An 8-week randomized double-blind clinical trial comparing GHK-Cu in nano-lipid carrier to Matrixyl 3000 showed 55.8% reduction in wrinkle volume versus control serum and 31.6% reduction versus Matrixyl 3000, with 32.8% reduction in wrinkle depth versus control
Product Information: FOXO4-DRI acetate is a cell-permeable peptide antagonist that blocks the interaction between FOXO4 and p53.FOXO4-DRI is an anti-aging peptide that induces apoptosis in senescent cells
Overnight (22:0010:00 h) fasting blood glucose (FBG) was measured with an Accu-Chek reflectance meter with Accu-Chek active test strips (Roche Diabetes Care, Mannheim, Germany) on experimental days P7, P14, P21, P28, and P38
Instead of escalating every 4 weeks, increases happen every 6-8 weeks in smaller increments (1.0-1.5 mg instead of 2.5 mg)
Pickart estimated the toxic dose for humans at approximately 22,500 mg, which sits roughly 3,750 times higher than a typical weekly therapeutic dose